Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035971 · ClinicalTrials.gov registry record · Phase 4
EVA: Evista Alendronate Comparison
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00035971: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT00035971 is a Phase 4 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035971, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures
Interventions
- DRUG raloxifene HCI and alendronate Na
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 4 |
What the finished NCT00035971 record still lists
NCT00035971 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which raloxifene HCI and alendronate Na is the first listed.
NCT00035971 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00035971 about?
NCT00035971 is a clinical study titled "EVA: Evista Alendronate Comparison". The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures
What is the current status of trial NCT00035971?
This trial is currently completed. It is a Phase 4 study.
What interventions are being tested in trial NCT00035971?
The interventions under investigation include: raloxifene HCI and alendronate Na (DRUG).
Who is sponsoring clinical trial NCT00035971?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.